Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
Kiyomi MoritaHagop M KantarjianKoiji SasakiGhayas C IssaNitin JainMarina KonoplevaNicholas James ShortKoichi TakahashiCourtney D D DiNardoTapan Mahendra KadiaGuillermo Garcia ManeroNaval G DaverGuillermo Montalban BravoJorge E CortesFarhad RavandiElias J JabbourPublished in: Cancer (2021)
The outcome of CML-LBP has improved with hyper-CVAD plus dasatinib therapy with survival comparable to that of Ph-positive ALL. Further improvement may be achieved with the use of novel TKIs and targeted agents.